Global Information
회사소개 | 문의 | 비교리스트

세계의 생물제제 시장 : 예측(2021-2026년)

Biologics Market - Forecasts from 2021 to 2026

리서치사 Knowledge Sourcing Intelligence
발행일 2021년 12월 상품코드 1060129
페이지 정보 영문 121 Pages 배송안내 1-2일 (영업일 기준)
US $ 3,950 ₩ 5,033,000 PDF (Single User License)
US $ 4,550 ₩ 5,797,000 PDF (Multiple User License)
US $ 6,950 ₩ 8,855,000 PDF (Enterprise License)

세계의 생물제제 시장 : 예측(2021-2026년) Biologics Market - Forecasts from 2021 to 2026
발행일 : 2021년 12월 페이지 정보 : 영문 121 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 생물제제 시장 규모는 2019년 2,699억 3,100만 달러에서 2026년까지 4,833억 9,300만 달러에 달하고, 8.68%의 CAGR로 성장할 것으로 예측됩니다.

중요한 시장 참여자에 의한 자금 투자 확대, 만성질환 부담 증가, 주요 생물학적 제제의 특허 독점권 상실 및 신규 치료에 대한 수요와 수용성 상승은 모두 이 업계를 견인하고 있습니다. 2018년 세계보건기구의 통계에 의하면 만성질환에 의해 매년 4,100만명 이상이 사망했습니다. 또한 증가하는 고령자 세대는 만성질환에 대해서 더 취약하고, 이것이 생물제제 수요 증가의 한 요인이 되고 있습니다.

세계의 생물제제(Biologics) 시장에 대해 조사 분석했으며, 시장 역학, 시장 분석, 경쟁 정보, 기업 개요 등 체계적인 정보를 제공합니다.


제1장 서론

  • 시장 개요
  • COVID-19 시나리오
  • 시장 정의
  • 시장 세분화

제2장 조사 방법

  • 조사 데이터
  • 가정

제3장 주요 요약

  • 조사 하이라이트

제4장 시장 역학

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • Porter's Five Forces 분석
    • 최종사용자의 협상력
    • 구매자의 협상력
    • 신규 참여업체의 위협
    • 대체품의 위협
    • 업계의 경쟁 기업간 경쟁 관계
  • 업계의 밸류체인 분석

제5장 세계의 생물제제 시장 분석 : 제품 종류별

  • 서론
  • 단일클론항체
  • 백신
  • 재조합 단백질
  • 유전자 치료
  • 세포 기반 생물제제
  • 기타

제6장 세계의 생물제제 시장 분석 : 용도별

  • 서론
  • 종양학
  • 신경학
  • 심장병학
  • 혈액학
  • 자가면역질환
  • 감염증
  • 기타

제7장 세계의 생물제제 시장 분석 : 지역별

  • 서론
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 남미
    • 브라질
    • 아르헨티나
    • 기타
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 스페인
    • 기타
  • 중동 및 아프리카
    • 사우디아라비아
    • 아랍에미리트
    • 남아프리카공화국
    • 기타
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 대만
    • 태국
    • 인도네시아
    • 기타

제8장 경쟁 환경과 분석

  • 주요 기업과 전략 분석
  • 신흥 기업과 시장 수익성
  • 합병, 인수, 합의 및 협업
  • 벤더 경쟁 매트릭스

제9장 기업 개요

  • F. Hoffmann-La Roche AG
  • Amgen Inc.
  • AbbVie Inc.
  • Novo Nordisk A/S
  • Johnson & Johnson
  • Takeda Pharmaceutical Company
  • Alexion Pharmaceuticals
  • Samsung Biologics
  • UCB S.A.
  • Merck & Co. Inc
  • Eli Lilly and Company
  • Sanofi SA
KSM 22.03.14

The global biologics market is projected to grow at a CAGR of 8.68% to reach US$483.393 billion by 2026, from US$269.931 billion in 2019. Biologics are medicines that are made up of genetically modified proteins obtained from human DNA. Biologics can be made up of carbohydrates, proteins, nucleic acids, or complex mixtures of these chemicals, or living things like cells and tissues, according to the US FDA. The majority of biologics are complex mixes that are difficult to describe or identify, are heat sensitive, and are prone to microbial contamination. Biologic products come from a wide range of natural sources, including animals, people, and microbes. Biologics are made using modern biotechnology techniques and complicated procedures. During the COVID-19 pandemic, there had been a large need for biologics because of the rising COVID-19 load, which may fuel market expansion. For example, the National Research Council of Canada and CanSino Biologics, located in China, partnered in May 2020 on the clinical development of a COVID-19 vaccine in Canada. Ad5-nCoV is an adenovirus Type 5 vector-based vaccination that is now in Phase II development in Wuhan, China. As a result, the biologics market is projected to increase in the near future due to substantial research and development activity on biologics for the treatment of COVID-19.

Growing financial investment from important market participants, an increase in the burden of chronic illnesses, the loss of patent exclusivity for top biologic medicines, and rising demand and acceptability for novel therapies are all driving the industry. Vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins are examples of biologics. The majority of biologics are complex mixes that are difficult to identify or describe, are heat sensitive, and are prone to microbial contamination. In the year 2018, due to increased demand for Merck's medicines and vaccines, the firm recently announced the construction of a second production unit for vaccines and biologics in Ireland. Chronic illnesses kill more than 41 million people each year, according to World Health Organization figures from 2018. The most common chronic disease, cardiovascular disease, kills 17.9 million people per year, followed by cancer (9.3 million), respiratory disorders (4.1 million), and diabetes (1.5 million). Eighty percent of all chronic disease fatalities are caused by these four categories. Non-communicable illnesses are caused by tobacco use, physical inactivity, alcohol use, and poor diets. Furthermore, the growing elderly population is more vulnerable to chronic illnesses, which contributes to an increase in biologics demand.

Growth Factors

Technological advancements and robust research and development will lead to market growth.

One of the major reasons for the growth of the global biologics market is the increasing technological advancements and robust research and development. These research and development efforts have resulted in higher success rates in biologics clinical trials. Market leaders in the biologics market do research and development as they try to achieve breakthroughs in the market in the form of new and effective biologics. Biocon Limited, for example, is working on tregopil, oral prandial insulin for the treatment of type 2 diabetes that is now in phase II/III clinical studies. Insulin tregopil is now being studied in Phase II/III clinical trials for Type 2 diabetic patients. Oramed Pharmaceuticals, located in Jerusalem, developed ORMD-0801, an oral insulin medication now in phase 2 studies to treat type 2 diabetes. The US Food and Medication Administration gave Novo Nordisk, a Danish multinational pharmaceutical firm, clearance to market its Rybelsus oral diabetic drug in September 2019. Rybelsus is an oral version of semaglutide that is used to treat type 2 diabetic patients. These advancements in technology have boosted the market growth of the global biologics market during the forecast period.


  • Market restraints might be imposed by strict regulatory criteria for biologics approval.

A major restraint in the growth of the global biologics market is the stringent regulatory requirements for biologics approval. In the projected term, the biologics market is expected to be hampered by strict rules placed on biologics approvals. The manufacture and use of biologics are governed by various regulations in different areas. Furthermore, difficulties such as patent infringement or contract concerns prevent biologics producers from commercializing government-approved biosimilars. These factors continue to hamper the growth of the global biologics market during the forecast period.

Impact of COVID-19 on the Biologics Market

The COVID-19 impact on the global biologics market has been positive owing to the rise in the demand for biologics during the COVID-19 pandemic. The rising technological advancements and the growing research and development to develop vaccines for the virus have been extensive resulting in the increasing demand for biologics. With the increasing COVID-19 pandemic, businesses in the United States are rushing to produce COVID-19 vaccinations. For example, in March 2020, Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle launched a Phase 1 clinical trial to investigate an experimental vaccination designed to protect against COVID-19. Scientists from the National Institute of Allergy and Infectious Diseases and its partners at the biotechnology firm Moderna Inc. are working on the vaccine. Also, the National Research Council of Canada and CanSino Biologics, located in China, partnered in May 2020 to develop a COVID-19 vaccine in Canada. Ad5-nCoV is an adenovirus Type 5 vector-based vaccination that is now in Phase II development in Wuhan, China. The surging demand for biologics during the course of the pandemic has fueled the market growth of the global biologics market.

Competitive Insights

The market leaders in the pretreatment coating market are F. Hoffmann-La Roche AG, Amgen Inc., AbbVie Inc., Novo Nordisk A/S, Johnson & Johnson, Takeda Pharmaceutical Company, Alexion Pharmaceuticals, Samsung Biologics, UCB S.A., Merck & Co. Inc, Eli Lilly, and Company, Sanofi SA


  • By Type

Monoclonal Antibodies


Recombinant Proteins

Gene Therapy


  • By Application



Orphan Indications

Infectious Diseases


  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others


  • UK
  • Germany
  • France
  • Spain
  • Others

Middle East and Africa

  • Saudi Arabia
  • Israel
  • Others

Asia Pacific

  • Japan
  • China
  • India
  • Indonesia
  • Taiwan
  • Thailand
  • Others

Table of Contents

1. Introduction

  • 1.1. Market Overview
  • 1.2. Covid-19 Scenario
  • 1.3. Market Definition
  • 1.4. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of End-Users
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Global Biologics Market Analysis, by Product Type

  • 5.1. Introduction
  • 5.2. Monoclonal Antibodies
  • 5.3. Vaccines
  • 5.4. Recombinant Proteins
  • 5.5. Gene Therapy
  • 5.6. Cellular-based Biologics
  • 5.7. Others

6. Global Biologics Market Analysis, by Application

  • 6.1. Introduction
  • 6.2. Oncology
  • 6.3. Neurology
  • 6.4. Cardiology
  • 6.5. Hematology
  • 6.6. Autoimmune Diseases
  • 6.7. Infectious Diseases
  • 6.8. Others

7. Global Biologics Market Analysis, by Geography

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. UK
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. South Africa
    • 7.5.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. Japan
    • 7.6.4. South Korea
    • 7.6.5. Taiwan
    • 7.6.6. Thailand
    • 7.6.7. Indonesia
    • 7.6.8. Others

8. Competitive Environment and Analysis

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. Company Profiles 

  • 9.1. F. Hoffmann-La Roche AG
  • 9.2. Amgen Inc.
  • 9.3. AbbVie Inc.
  • 9.4. Novo Nordisk A/S
  • 9.5. Johnson & Johnson
  • 9.6. Takeda Pharmaceutical Company
  • 9.7. Alexion Pharmaceuticals
  • 9.8. Samsung Biologics
  • 9.9. UCB S.A.
  • 9.10. Merck & Co. Inc
  • 9.11. Eli Lilly and Company
  • 9.12. Sanofi SA
Back to Top
전화 문의